Opinion|Videos|August 21, 2024
Ensuring Informed CML Care from Diagnosis Onward
Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- As patients progress through their CML journey, how does the focus of shared decision-making evolve between the patient, caregiver, and healthcare team? What are some of the key challenges or changes you've observed in the patient, physician, and caregiver role over time?
- What advice would you direct to patients and caregivers in navigating these changes?
- What advice would you direct to patients and caregivers in navigating these changes?
Advertisement
Related to this article
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.
Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.
Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.
Diagnosed with leukemia at 8 years old, Harper feared that losing her hair would change who she was. She reflects on body image, confidence and finding a sense of herself during cancer treatment.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
What New KRAS Drug Data From ESMO 2026 Mean for Patients
3
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
4
Imdelltra Plus Imfinzi Extends Survival in Small Cell Lung Cancer
5